

205

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. _____ S. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-051365- -00004-0000

Fecha: 2008-11-14 17:09:57 Dep. 2020 NUECREACION
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 538 PETICION Folios: 2

Ref: Expediente N°. 07-051.365

Solicitud de Patente de Invención titulada: "DERIVADOS DE N-[(3S)-
PIRROLIDIN-3-IL]- BENZAMIDA COMO INHIBIDORES DE LA
RECAPTACIÓN DE MONOAMIDAS".


Solicitante: PFIZER INC.

Nuestra Ref.: P2007/000087

SOLICITUD DE EXAMEN DE PATENTABILIDAD SEGÚN
EL ARTÍCULO 44 DE LA DECISION 486, GACETA No. 596

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá, D.C., identificado tal como aparece al pie de mi firma, en mi condición de apoderado, respetuosamente me permito solicitar que se examine si la invención reúne los requisitos de patentabilidad previstos en la misma, dando cumplimiento a lo establecido en el artículo 44 de la Decisión 486 de la comisión de la Comunidad Andina. Adjunto recibo por el monto de \$210.000 pesos para cubrir la tasa correspondiente, según la Resolución 44372 del año 2007.

Atentamente,


CARLOS R. OLARTE
C.C. 79.782.747 de Bogotá
T.P. 74.295

Anexo: Recibo por \$210.000 pesos

206

2

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-051365- -00004-0000

Fecha: 2008-11-14 17:09:57 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 538 PETICION Folios: 2

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 08 - 89,268
FECHA : NOVIEMBRE 13 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
OLARTE RAISBEK	CONSIGNACION	BANCO DE BOGOTA	062754387	81235490	12/11/2008	4,818,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-01	SOLICITUDES	
		114 PTC CAP-II EXAMEN DE PATENTIBILID	210,000.00
		TOTAL :	\$ 210,000.00

SON: DOSCIENTOS DIEZ MIL PESOS

RESPONSABLE : _____

207.



Industria y Comercio
SUPERINTENDENCIA

DIVISIÓN DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 07-51365

EL EXTRACTO DE LA PRESENTE SOLICITUD DE **PATENTE DE INVENCION**

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No **596** DE

FECHA **30 DE SEPTIEMBRE DE 2008** EL TÉRMINO HÁBIL SEÑALADO POR

LA LEY EXPIRA EL **30 DE DICIEMBRE DE 2008**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____

NO X

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 June 2006 (01.06.2006)

PCT

(10) International Publication Number
WO 2006/056884 A1(51) International Patent Classification:
C07D 207/14 (2006.01) A61K 31/40 (2006.01)Kent CT13 9NJ (GB). WHITLOCK, Gavin, Alistair
[GB/GB]; Pfizer Global Research and Development,
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).(21) International Application Number:
PCT/IB2005/003643(74) Agent: DROUIN, Stephane; Pfizer Research and Devel-
opment, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).(22) International Filing Date:
18 November 2005 (18.11.2005)(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0425766.3 23 November 2004 (23.11.2004) GB(71) Applicant (for GB only): PFIZER LIMITED [GB/GB];
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).(71) Applicant (for all designated States except GB, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): FISH, Paul, Vin-
cent [GB/GB]; Pfizer Global Research and Development,
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). RYCK-
MANS, Thomas [BE/GB]; Pfizer Global Research and
Development, Ramsgate Road, Sandwich, Kent CT13 9NJ
(GB). STOBIE, Alan [GB/GB]; Pfizer Global Research
and Development, Ramsgate Road, Sandwich, Kent CT13
9NJ (GB). WAKENHUT, Florian [FR/GB]; Pfizer Global
Research and Development, Ramsgate Road, Sandwich,(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: N-[(3S)-PYRROLIDIN-3-YL]-BENZAMIDE DERIVATIVES AS MONOAMINE RE-UP TAKE INHIBITORS

(57) Abstract: A compound of Formula (I) and pharmaceutically and/or
veterinarily acceptable derivatives thereof, wherein: R¹, R², R³ and R²⁰ are
each independently H, Cl, Br, F, I, CF₃, OCF₃, Me or Et; R⁴ is het or C₃₋₇
cycloalkyl optionally substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, alkoxyalkyl con-
taining 2 to 4 carbon atoms or -S-(C₁₋₄ alkyl); a is 0 or 1; and het is a non-aro-
matic 4-, 5- or 6- membered heterocycle which contains at least one N, O
or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group
or a second 4-, 5- or 6- membered heterocycle which contains at least one
N, O or S heteroatom, wherein the het group is optionally substituted by
at least one substituent independently selected from C₁₋₈ alkyl, C₁₋₈ alkoxy,
OH, halo, CF₃, OCF₃, SCF₃, hydroxy-C₁₋₆ alkyl, C₁₋₄ alkoxy-C₁₋₆ alkyl and
C₁₋₄ alkyl-S-C₁₋₄ alkyl; provided that at least one of R¹, R² and R³ are otherthan H. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have
utility in a variety of therapeutic areas, for example urinary incontinence.

INTERNATIONAL SEARCH REPORT

IB2005/003643

209

A. CLASSIFICATION OF SUBJECT MATTER C07D207/14 A61K31/40		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CH 628 885 A (ANPHAR SA) 31 March 1982 (1982-03-31) X abstract; claim 1	1-21
A	NORMAN T R ET AL: "NEW PHARMACOLOGICAL APPROACHES TO THE MANAGEMENT OF DEPRESSION; FROM THEORY TO CLINICAL PRACTICE" AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, MELBOURNE, AU, vol. 26, 1992, pages 73-81, XP002066745 ISSN: 0004-8674 abstract → Art 4c	1-21
P, X	WO 2004/111003 A (PFIZER LIMITED; ANDREWS, MARK, DAVID; BROWN, ALAN, DANIEL; FRADET, DAV) 23 December 2004 (2004-12-23) X claims 1,9-13; examples 29,34 ----- -/--	1-21
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the International filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
3 February 2006		13/02/2006
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Jenn, T

INTERNATIONAL SEARCH REPORT

IB2005/003643

210

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2004/110995 A (PFIZER LIMITED; FISH, PAUL, VINCENT; FRAY, MICHAEL, JONATHAN; LOVERING) 23 December 2004 (2004-12-23) claims 1,13-23; examples 1-8,13-15 -----	1-21